One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.

Peter J GoadsbyUwe ReuterYngve HallströmGregor BroessnerJo H BonnerFeng ZhangIan K WrightDenise E ChouJan KlattHernan PicardRobert A LenzDaniel D Mikol

Published in: Neurology (2020)

Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.

Keyphrases

open label
randomized controlled trial
clinical trial